Unlock Insights into IBD Research | Specialized Experimental Model Solutions

At Ace Therapeutics, we provide well-established DNBS-induced colitis models customized to your therapeutic strategy. Our platform offers flexible study design, robust endpoints, and translational insights to accelerate your IBD drug discovery program.

Why Choose Our DNBS-Induced Colitis Models?

• Clinically Relevant Pathophysiology: Our DNBS-induced colitis model closely mirrors key features of CD colitis, including Th1/Th17-driven inflammation, mucosal ulceration, and immune cell infiltration.
• Rapid and Reproducible Induction: Using a single intrarectal DNBS/ethanol administration, our model induces consistent inflammation within 6 days, enabling rapid screening of drug candidates while maintaining robust immunopathological features.
• Flexible Study Design: Whether your goal is mechanistic exploration, drug efficacy evaluation, or biomarker discovery, we tailor study parameters, including animal species, dosing strategy, and observation period, to align precisely with your research objectives.

Comprehensive Readouts and Analytical Capabilities

• Clinical and macroscopic measures: Body weight, stool consistency, fecal blood, colon length, and Disease Activity Index (DAI).
• Histological evaluation: Detailed mucosal analysis using H&E and IHC.
• Cytokine and molecular profiling: TNF-α, IL-1β, IL-6, IL-17, IFN-γ, and oxidative stress markers quantified via ELISA/qPCR.
• Advanced imaging: Endoscopy, CT, MRI, and PET/CT for real-time assessment of disease severity.

Accelerate your Crohn's disease research with our validated DNBS-induced colitis model. Download the brochure to discover how Ace Therapeutics can help advance your preclinical IBD research.

You might be interested in...